Multiplexed ACE2 Profiling Reveals SARS-CoV-2 Variant Adaptation

Study Background and Research Question

The compatibility between viral entry proteins and host cell receptors is a critical determinant of infection and host range. Since the start of the COVID-19 pandemic, the rapid emergence of SARS-CoV-2 variants has been accompanied by recurrent mutations in the spike (S) protein, particularly within its receptor-binding domain (RBD). These changes have raised pressing questions: Do variant spikes shift their usage of angiotensin-converting enzyme 2 (ACE2) receptors, and could such adaptation facilitate cross-species transmission?

Traditional approaches have limited throughput and cannot systematically test all possible combinations of viral entry proteins and host receptor variants. Addressing this gap, Shukla et al. (2024) devised a scalable solution to map the interplay between SARS-CoV-2 spike variants and ACE2 diversity in their recent study.

Key Innovation from the Reference Study

The central innovation in this work is a multiplexed infection assay that allows for the simultaneous interrogation of dozens of ACE2 receptor sequence variants against different SARS-CoV-2 spike proteins. The method leverages pseudotyped viruses—lentiviral particles engineered to present SARS-CoV-2 spike proteins on their surface—alongside a barcoded library of target cells expressing distinct ACE2 orthologs or mutants. The infection efficiency of each spike-receptor pair is read out through high-throughput DNA barcode sequencing.

This approach enables systematic, high-resolution mapping of the combinatorial sequence space between viral and host proteins, overcoming the throughput limitations of pairwise assays. Notably, the platform is extensible to other viral entry and receptor systems, offering a blueprint for large-scale studies of protein compatibility during infection.

Methods and Experimental Design Insights

In their experimental workflow, the authors constructed a library consisting of 30 ACE2 variants: 17 animal orthologs and 13 engineered human mutants reflecting natural sequence diversity. Each ACE2 variant was expressed in a human cell line, with each cell population uniquely barcoded for downstream identification.

Pseudotyped lentiviruses displaying spike proteins from the original SARS-CoV-2 strain and five variants of concern (Alpha, Beta, Gamma, Delta, Omicron BA.1) were generated. The cell library was then pooled and exposed to each pseudovirus in parallel infection assays. Post-infection, next-generation sequencing of DNA barcodes quantified the infectivity across all ACE2-spike combinations.

Complementary structural modeling was performed to analyze how specific spike mutations altered the interaction interface with human ACE2, providing mechanistic context for observed shifts in receptor usage.

Core Findings and Why They Matter

The multiplexed profiling revealed several important findings (Shukla et al., 2024):

• Human ACE2 Tolerance: Despite accumulating mutations, all tested SARS-CoV-2 variant spikes retained efficient usage of the canonical human ACE2, with only modest changes in infectivity.
• Expanded Animal ACE2 Compatibility: Variants displayed pronounced, idiosyncratic shifts in their capacity to utilize non-human ACE2 orthologs. Out of 13 non-human ACE2s, 10 exhibited unique, variant-specific compatibility patterns, demonstrating that spike mutations can toggle or broaden host range potential.
• N501Y and Structural Shifts: The N501Y substitution, present in Alpha, Beta, Gamma, and Omicron, induced major structural changes in the spike-ACE2 interface, strongly influencing which animal ACE2s could be engaged. Interestingly, indirect effects of other mutations in Delta partially recapitulated the N501Y-induced shift, despite the absence of this residue.
• Cumulative Expansion: The collective effect of sequential variant emergence was an overall increase in the spectrum of ACE2s compatible with SARS-CoV-2, supporting a model where viral evolution during human transmission can facilitate future cross-species jumps.

These results provide a quantitative map of variant-specific receptor compatibility, enhancing our understanding of viral adaptation and zoonotic risk.

Comparison with Existing Internal Articles

The findings from Shukla et al. are complementary to the platform-oriented review in "Multiplexed ACE2 Profiling Reveals SARS-CoV-2 Variant Adaptation", which contextualizes the need for high-throughput compatibility mapping in viral pathogenesis research. The review underscores the utility of such multiplexed approaches in anticipating variant-driven shifts in host tropism.

Furthermore, internal resources such as "AP1903: Unlocking Precision in FKBP Dimerization and Cell Control" and "AP1903: Precision FKBP-Binding Ligand for Conditional Cell Ablation" highlight the role of chemical biology tools like AP1903 in enabling high-throughput, conditional control over protein function and cell fate—capabilities that can be integrated into advanced infection and compatibility assays.

Limitations and Transferability

While the multiplexed pseudovirus assay offers unprecedented throughput and resolution, certain limitations should be considered:

• The assay uses engineered lentiviruses and overexpressed ACE2 in human-derived cells, which may not fully recapitulate natural receptor expression levels or post-translational modifications in vivo.
• Only a finite set of ACE2 variants was tested, and the impact of co-receptors or other host factors was not addressed.
• Structural modeling, while informative, represents a static view and may not capture allosteric or dynamic effects in protein interactions.

Nevertheless, the approach is highly transferable to other virus-receptor pairs and can be adapted to profile compatibility landscapes in different host or tissue contexts.

Protocol Parameters

• ACE2 library construction: Clone desired ACE2 orthologs or mutants into lentiviral vectors, ensuring each variant is linked to a unique DNA barcode for downstream demultiplexing.
• Pseudovirus generation: Produce lentiviral particles pseudotyped with spike proteins from target SARS-CoV-2 variants using standard lentiviral packaging systems.
• Library pooling and infection: Mix barcoded ACE2-expressing cell lines at defined ratios; infect with normalized input of pseudovirus for parallelized infection readout.
• Barcode quantification: After infection, extract genomic DNA and amplify barcode regions for next-generation sequencing to assess infection efficiency per ACE2 variant.
• Data analysis: Normalize barcode counts and calculate relative infectivity across all spike-ACE2 pairs; integrate with structural modeling for mechanistic interpretation.

Why this cross-domain matters, maturity, and limitations

This study bridges virology, protein engineering, and high-throughput screening, offering a mature platform for dissecting protein-protein compatibility at scale. The methodology is well-suited for mapping host range evolution in emerging viruses, and its modular design allows rapid adaptation to novel pathogens or receptor families. However, its predictive power for in vivo transmission events is limited by cell line context and the artificial nature of pseudotyped systems.

Research Support Resources

For researchers aiming to implement high-throughput, barcoded cell-based assays or conditional cell ablation in the context of receptor compatibility studies, robust chemical tools are essential. AP1903 (SKU B4168) from APExBIO is a synthetic FKBP-binding ligand widely used in conditional cell ablation and controlled protein activation workflows. AP1903 enables precise, tunable control of FKBP fusion proteins—facilitating rigorous interrogation of apoptosis pathways and supporting advanced multiplexed assay designs relevant to the innovations described in this study.